CDEK
← All drugs Report issue

oblimersen sodium

Nucleic acidexperimental

Clinical trial activity

45 trials · 23 clinical orgs · 0 marketing orgs

Phase 1
22
Phase 2
29
Phase 3
8
Phase 4
0

Earliest trial started Aug 1, 1997 (NCT00003103)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2000

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bcl-2 antisense oligodeoxynucleotide
  • dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t)
  • dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t)
  • dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t) hepatadecasodium salt
  • g3139
  • g3139
  • g3139
  • g3139
  • g3139
  • g3139
  • g 3139
  • g-3139 oligonucleotide
  • g3139 oligonucleotide
  • genasense
  • genasense
  • genasense
  • genasense
  • genasense
  • oblimersen
  • oblimersen
  • oblimersen
  • oblimersen
  • oblimersen
  • oblimersen
  • oblimersen sodium
  • oblimersen sodium
  • oblimersen sodium
  • oblimersen sodium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01200342Phase 2Dec 1, 2010Genta, University of Texas at Houston
NCT00736450N/AJul 1, 2008Genta, National Cancer Institute (NCI), University of Nebraska
NCT00518895Phase 3Jul 1, 2007Genta
NCT00636545Phase 1May 1, 2007Genta
NCT00409383Phase 1Nov 1, 2006Genta, New York University
NCT00517218Phase 3Jun 1, 2006Genta
NCT00543075Phase 1May 1, 2006Davita Clinical Research, Genta
NCT00542893Phase 1Apr 1, 2006Genta
NCT00301795Phase 2Mar 1, 2006Cancer and Leukemia Group B (CALGB), National Cancer Institute (NCI)
NCT00543231Phase 1Dec 1, 2005Genta
NCT00091078Phase 2Sep 1, 2005National Cancer Institute (NCI), University of Texas at Houston
NCT00543205Phase 2/Phase 3 (Phase 3)Aug 1, 2005Genta
NCT00086944Phase 1/Phase 2 (Phase 2)May 1, 2004National Cancer Institute (NCI), University of Chicago
NCT00085228Phase 2Apr 1, 2004Azienda Ospedaliera San Camillo Forlanini, European Organisation for Research and Treatment of Cancer
NCT00080847Phase 2Mar 1, 2004National Cancer Institute (NCI), Southwest Oncology Group
NCT00079131Phase 2Jan 1, 2004Cornell University, National Cancer Institute (NCI)
NCT00085124Phase 3Dec 1, 2003Cancer and Leukemia Group B (CALGB), National Cancer Institute (NCI)
NCT00078234Phase 1/Phase 2 (Phase 2)Nov 1, 2003Genta
NCT00070343N/AAug 1, 2003National Cancer Institute (NCI), University of California, Los Angeles
NCT00059813Phase 2Aug 1, 2003City of Hope National Medical Center, National Cancer Institute (NCI)
Showing 20 of 45 trials
Page 1 / 3

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government281941999
GentaFor profit171542000
University of Texas at HoustonAcademic/Hospital6112000
Cancer and Leukemia Group B (CALGB)Academic/Hospital4022002
University of ChicagoAcademic/Hospital3122000
Cornell UniversityAcademic/Hospital2111997
Ohio State UniversityAcademic/Hospital2011999
University of Texas, San AntonioAcademic/Hospital2212000
Azienda Ospedaliera San Camillo ForlaniniAcademic/Hospital1012004
British Columbia Cancer AgencyAcademic/Hospital1112003
City of Hope National Medical CenterAcademic/Hospital1012003
Davita Clinical ResearchFor profit1012006
European Organisation for Research and Treatment of CancerAcademic/Hospital1112004
Mayo ClinicAcademic/Hospital1012003
New York UniversityAcademic/Hospital1012006
Southwest Oncology GroupAcademic/Hospital1012004
Stanford UniversityAcademic/Hospital1012003
University of California, Los AngelesAcademic/Hospital1112003
University of MarylandAcademic/Hospital1112002
University of NebraskaAcademic/Hospital1112008
23 organizations
Page 1 / 2